Skip to main content
. 2024 Feb 22;18(9):6845–6862. doi: 10.1021/acsnano.3c04471

Figure 6.

Figure 6

Nanoparticle vaccine provides therapeutic efficacy in MC38 adenocarcinoma model and improves the efficacy of αPD-1 ICB therapy. (A) Tumor challenge and therapeutic vaccination scheme. (B) Spider plots of individual tumor growth curves. (C) Average MC38 tumor growth in response to indicated formulation (mean ± SEM; n = 10 mice/group). (D) Average tumor volume on day 22 after tumor inoculation (mean ± SEM; n = 10 mice/group; *P < 0.05; one-way ANOVA with Tukey’s multiple comparisons). (E) Kaplan–Meier survival curve using 2000 mm3 tumor volume as the end point (n = 10 mice/group; statistical significance between NP-Pep/cGAMP/MPLA(1:4) and all other groups shown; *P < 0.05; Mantel–Cox log-rank test). (F) Tumor challenge, therapeutic vaccination, and αPD-1 treatment scheme. (G) Spider plots of individual tumor growth curves. (H) Average MC38 tumor growth in response to indicated formulation (mean ± SEM; n = 8–10 mice/group). (I) Average tumor volume on days 17–25 after tumor inoculation (mean ± SEM; n = 8–10 mice/group; *P < 0.05, **P < 0.01; one-way ANOVA with Tukey’s multiple comparisons). (J) Kaplan–Meier survival curve using 2000 mm3 tumor volume as the end point (n = 8–10 mice/group; statistical significance between NP-Pep/cGAMP/MPLA(1:4) + αPD-1 and all other groups shown; *P < 0.05; Mantel–Cox log-rank test).